U.S. FDA authorizes Eli Lilly's COVID-19 antibody drug – Reuters.com

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake
Feb 11 (Reuters) – The U.S. Food and Drug Administration on Friday authorized Eli Lilly and Co's (LLY.N) COVID-19 antibody drug for people aged 12 and older at risk of severe illness, adding a tool that has been found to work against the highly contagious Omicron variant.
The FDA authorized bebtelovimab for emergency use in patients with mild-to-moderate COVID-19 who are at high risk of progression to severe disease, including hospitalization or death.
Bebtelovimab should be used when alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate, the agency said.
The U.S. health regulator had in January revised the emergency use authorizations for Lilly's antibody combination treatment and a rival therapy from Regeneron (REGN.O) after the drugs were found to be ineffective against the Omicron variant.
Lilly has said bebtelovimab retains activity against Omicron as well as its BA. 2 subvariant, which is said to be more transmissible.
The company on Thursday signed a supply deal with the U.S. government for up to 600,000 doses of bebtelovimab to be delivered by the end of March.
Bebtelovimab was originally discovered by AbCellera Biologics (ABCL.O) and later licensed and developed by Eli Lilly.
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved


Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart